UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 6.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 159,729 shares of the biotechnology company’s stock after selling 10,886 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.75% of Enanta Pharmaceuticals worth $918,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Tower Research Capital LLC TRC boosted its stake in shares of Enanta Pharmaceuticals by 46.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 2,274 shares during the period. AlphaQuest LLC boosted its stake in shares of Enanta Pharmaceuticals by 16.4% in the fourth quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 3,137 shares during the period. Invesco Ltd. boosted its stake in Enanta Pharmaceuticals by 7.3% during the 4th quarter. Invesco Ltd. now owns 46,614 shares of the biotechnology company’s stock valued at $268,000 after acquiring an additional 3,186 shares during the last quarter. American Century Companies Inc. boosted its stake in Enanta Pharmaceuticals by 10.5% during the 4th quarter. American Century Companies Inc. now owns 36,962 shares of the biotechnology company’s stock valued at $213,000 after acquiring an additional 3,501 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Enanta Pharmaceuticals by 69.6% during the 4th quarter. Wells Fargo & Company MN now owns 15,881 shares of the biotechnology company’s stock valued at $91,000 after acquiring an additional 6,518 shares during the last quarter. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on ENTA. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. JMP Securities increased their price objective on shares of Enanta Pharmaceuticals from $23.00 to $24.00 and gave the company a “market outperform” rating in a research note on Tuesday, June 3rd. Finally, Wall Street Zen upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ:ENTA opened at $7.58 on Wednesday. The stock has a market capitalization of $162.04 million, a price-to-earnings ratio of -1.53 and a beta of 0.76. Enanta Pharmaceuticals, Inc. has a 1-year low of $4.09 and a 1-year high of $17.24. The company’s fifty day moving average is $5.62 and its two-hundred day moving average is $6.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.02). The business had revenue of $14.93 million for the quarter, compared to analyst estimates of $15.96 million. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. Sell-side analysts expect that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.